Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats

Life Sciences

Volumn 73, Issue 25, 2003, Pages 3235-3244

  Kaya, M ^a   Kalayci, R ^b   Kucuk M ^b   Arican, N ^a   Elmas, I ^a   Kudat, H ^a   Korkut, F ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Alloxan; Blood brain barrier; Evans blue; Hypertension; L NAME

Indexed keywords

ADRENALIN; ALBUMIN; ALLOXAN; EVANS BLUE; LOSARTAN; N(G) NITROARGININE METHYL ESTER;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; BRAIN CORTEX; BRAIN LEVEL; BRAIN REGION; BRAIN TISSUE; CEREBELLUM; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIENCEPHALON; DRUG EFFECT; HYPERGLYCEMIA; HYPERTENSION; MICROVASCULATURE; NONHUMAN; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM;

EID: 0141892821     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.06.014     Document Type: Article

References (41)

1. Abbott R.D., Donahue R.P. Diabetes and the risk of stroke. JAMA. 257(7):1987;949-952.
2. Albrecht E.W., Stegeman C.A., Heeringa P., Henning R.H., van Goor H. Protective role of endothelial nitric oxide synthase. Journal of Pathology. 199(1):2003;8-17.
3. Barsotti A., Di Napoli P., Taccardi A.A., Spina R., Stuppia L., Palka G., Barbacane R.C., DeCaterina R., Conti P. MK-954 (losartan potassium) exert endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia. Atherosclerosis. 155:2001;53-59.
4. Blackshear J.L., Schwartz G.L. Step care therapy for hypertension in diabetic patients. Mayo Clinic Proceeding. 76:2001;1266-1274.
5. Blezer E.L., Nicolay K., Koomans H.A., Joles J.A. Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. American Journal of Hypertension. 14(1):2001;54-61.
6. Bryant C.E., Allcock G.H., Warner T.D. Comparison of effects of chronic and acute administration of NG-nitro-L-arginine methyl ester to the rat on inhibition of nitric oxide-mediated responses. British Journal of Pharmacology. 114(8):1995;1673-1679.
7. Cheetham C., Collis J., O'Driscoll G., Stanton K., Taylor R., Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. Journal of American College of Cardiology. 36:2000;1461-1466.
8. Contreras F., Rivera M., Vasquez J., De la Parte M.A., Velasco M. Diabetes and hypertension physiopathology and therapeutics. Journal of Human Hypertension. (Suppl 1):2000;S26-S31.
9. Cosentino F., Hishikawa K., Katusic Z.S., Luscher T.F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation. 96:1997;25-28.
10. Goehkle P., Linz W., Sckolkens B.A., Wiemer G., Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 28:1996;397-402.
11. Halcak L., Pechanova O., Zigova Z., Klemova L., Novacky M., Bernatova I. Inhibition of NO synthase activity in nervous tissue leads to decreased motor activity in the rat. Physiological Research. 49:2000;143-149.
12. Hornig B., Landmesser U., Kohler C., Ahlersmann D., Spiekermann S., Christoph A., Tatge H., Drexler H. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease. Circulation. 103:2001;799-805.
13. Johansson B.B. Hypertension. Pardridge W.M. The Introduction to the Blood-Brain Barrier. Methodology, Biology and Pathology. 1998;427-433 Cambridge University Press, Cambridge.
14. Kakinuma Y., Hama H., Sugiyama F., Yagami K.-I., Goto K., Murakami K., Fukamizu A. Impaired blood-brain barrier function in angiotensinogen-deficient mice. Nature Medicine. 4(9):1998;1078-1080.
15. Kalliovalkama J., Jolma P., Tolvanen J.P., Kahönen M., Kahönen N.H., Wu X., Holm P., Pörsti I. Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism. Cardiovascular Research. 42:1999;773-782.
16. Kubes P., Granger D.N. Nitric oxide modulates microvascular permeability. American Journal of Physiology. 262:1992;H611-H615.
17. Küçük M., Kaya M., Kalayci R., Cimen V., Kudat H., Arican N., Elmas I., Korkut F. Effects of losartan on the blood-brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats. Life Sciences. 71:2002;937-946.
18. Lippoldt A., Kniesel U., Liebner S., Kalbacher H., Kirsch T., Wolburg H., Haller H. Structural alterations of tight junctions are associated with loss of polarity in stroke-prone spontaneously hypertensive rat blood-brain barrier endothelial cells. Brain Research. 885(2):2000;251-261.
19. Lorenzi M., Healy D.P., Hawkins R., Printz J.M., Printz M.P. Studies on the permeability of the blood-brain barrier in experimental diabetes. Diabetologia. 29(1):1986;58-62.
20. Maeso R., Navarro-Cid J., Munoz-Garcia R., Rodrigo E., Ruilope L.M., Lahera V. Losartan reduces phenylephrine constictor response in aortic rings from SHR: role of NO and AT2 receptors. Hypertension. 28(6):1996;967-972.
21. Marry J., McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs. 56(2):1998;189-202.
22. Mayhan W.G. Effect of diabetes mellitus on disruption of the blood-brain barrier during acute hypertension. Brain Research. 534:1990;106-110.
23. Mayhan W.G. Inhibition of nitric oxide synthase does not alter permeability of the blood-brain barrier. Brain Research. 855:2000;143-149.
24. Mehta J.L., Li D. Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radical Biology and Medicine. 30(2):2001;148-153.
25. Mikawa S., Kinouchi H., Kamii H., Gobbell G.T., Chen S.F., Carlson E., Epstein C.J., Chan P.H. Attenuation of acute and chronic damage following traumatic brain injury in copper, zinc-superoxide dismutase transgenic mice. Journal Neurosurgery. 85:1996;885-891.
26. Mooradian A.D. Central nervous system complications of diabetes mellitus-a perspective from the blood-brain barrier. Brain Research Reviews. 23(3):1997;210-218.
27. Morton J.J., Beattie E.C., Speirs A., Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of rennin and vascular hypertrophy. Journal of Hypertension. 11:1993;1083-1088.
28. Nishimura Y., Ito T., Saavedra J.M. Angiotensin II blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 31:2000;2478-2486.
29. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. The Journal of Clinical Investigation. 97:1996;1916-1923.
30. Raje R., Ahmad S. Effect of experimental diabetes on the protection by angiotensin blockers on nitric oxide deficient stroke in stroke-prone spontaneously hypertensive rats. Clinical Experimental Hypertension. 21:1999;37-49.
31. Rumbout R.E., Harris N.R., Sial A.J., Huxley V.H., Granger D.N. Leakage responses to L-NAME differ with the fluorescent dye used to label albumin. American Journal of Physiology. 276:1999;H333-H339.
32. Rumbaut R.E., Huxley V.H. Similar permeability responses to nitric oxide synthase inhibitors of venules from three animal species. Microvascular Research. 64:2002;21-31.
33. Salameh A., Zinn M., Dhein S. High D-glucose induces alterations of endothelial cell structure in a cell culture model. Journal of Cardiovascular Pharmacology. 30:1997;182-190.
34. Shaohua Y., Zhong H., Duong V.N., Campese V.M. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension. 39(6):2002;1101-1106.
35. ω-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation. 106:2002;1729-1735.
36. Tour U.I., Edvinsson L., McCulloch J. Catecholamines and the relationship between cerebral blood flow and glucose use. American Journal Physiology. 251(4Pt 2):1986;H824-H833.
37. Vacher E., Richer C., Giudicelli J.F. Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. Journal of Hypertension. 14(11):1996;1341-1348.
38. Velasco P.L.P., Martin F.J.M. Effects of losartan and diltiazem on blood pressure, insulin sensitivity, lipid profile and microalbuminuria in hypertensive type 2 diabetic patients. Clinical Drug Investigation. 16:1998;361-370.
39. Wong P.C., Price W.A., Chiu A.T., Duncia J.V., Carini D.J., Wexler R.R., Johnson A.L., Timmermans P.B. Nonpeptide Angiotensin II receptor antagonists: VIII. Characterization of functional antagonism displayed by DuP753, an orally active antihypertensive agent. Journal of Pharmacology and Experimental Therapy. 252:1990;719-725.
40. Zhang H., Schmeisser A., Garlichs C.D., Plotze K., Damme U., Mugge A., Daniel W.G. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH/NADPH-oxidases. Cardiovascular Research. 44:1999;215-222.
41. Zhang X.M., Ellis E.F. Superoxide dismutase reduces permeability and edema induced by hypertension in rats. American Journal of Physiology. 259:1990;H497-H503.